Dangerous Drugs and Defective Products
If you've been hurt by a medical product, we'll fight for the justice you deserve
Every manufacturer has a responsibility to produce safe, effective products and to warn consumers about any dangers that may emerge. Pharmaceutical companies and medical equipment manufacturers have a particularly grave responsibility because their products are designed to treat disease and save lives. When they fail in that responsibility, people can be seriously hurt or even killed.
Call Now If You or a Loved One Was Harmed By Any Products Below
- Viagra, Levitra, Cialis
Defective drugs and medical devices can cause harm in several ways. Sometimes, they simply don't work - which means people who depend on them are left with an untreated medical condition. In other cases, these products have side effects that are actively harmful to the body, ranging from headaches, nausea and vomiting to depression, anxiety and suicidal thoughts.
Dangerous products reach the market for several reasons. For instance, companies may rush products through the market without rigorous testing, using a "fast track" through the approval process. Sometimes, the design of a medical product is flawed; on other occasions, a properly designed product is made unsafe due to manufacturing errors. Issues also emerge when physicians prescribe drugs for purposes other than their intended use, known as "off-label" use.
Dangerous drug cases demand strong legal action. When you're going up against a pharmaceutical manufacturer, you need to make sure you give your case the attention it rightfully deserves. Drug companies routinely hire teams of lawyers to defend their interests, especially if they've been accused of making and marketing dangerous drugs to the public. An experienced attorney can investigate your claim and build a strong case against the drug company.
Don’t take chances when your future is at stake. Let the veteran attorneys at The Herrera Law Firm fight for the justice you need. Contact us for a free case evaluation.
Accutane (isotretinoin) was prescribed to treat severe acne or recalcitrant cystic nodular acne. The Food and Drug Administration (FDA) introduced Accutane in 2002, but withdrew the drug in July 2009. Prior to being pulled from the market, Accutane had yearly sales of more than $1.2 billion. Accutane worked by shrinking the oil glands in the skin.
Accutane is reported to have severe side effects, including risk of inflammatory bowel disease (IBD), birth defects, Crohn's disease, ulcerative colitis, depression and suicide. Some studies have also linked Accutane use to an increased risk of colon cancer.
Frequently prescribed to people suffering from type 2 diabetes, Invokana is a medication that helps to lower a person's blood sugar. When used in combination with diet and exercise, Invokana causes the kidneys to remove sugar through urine, lowering blood sugar and improving glycemic control.
However, because Invokana affects the kidneys, it has been associated with kidney failure - a serious medical condition that can cause toxins and fluid to build up in the body. This leads to symptoms ranging from weakness and confusion to sudden death. Invokana use has also been associated with heart attack and ketoacidosis - a medical condition in which high levels of toxic acids build up in the bloodstream.
Janssen Pharmaceuticals, which manufactures Invokana, has faced multiple lawsuits alleging that the drug company failed to warn patients and doctors about the serious dangers associated with the drug. Nevertheless, the company has not taken action to discontinue the medication or to notify users of the potential risks. If you or a loved one has become seriously ill after taking Invokana, contact our attorneys today to protect your legal rights.
Lipitor (atorvastatin) is prescribed to address heightened cholesterol levels. Many people who have used Lipitor and other statin medications have developed diabetes and even kidney failure. Pfizer, the manufacturer of Lipitor, is facing hundreds of lawsuits alleging its drug caused diabetes.
A warning from the U.S. Food and Drug Administration in 2012 stated that some statins, including Lipitor, may lead to an increased risk of elevated blood glucose levels and the development of type 2 diabetes. The federal agency ordered Pfizer to include a warning on its label informing consumers about the risk.
Because some Lipitor users developed type 2 diabetes before the label change, we believe Pfizer failed to warn users of the risk, which means the corporation must be held accountable. Even with the label change, we believe consumers do not have enough information about the risks to make an informed decision.
In 2014, a Canadian study found Lipitor, Zocor, Crestor and other statins pose serious health risks to users. The findings raise questions about whether these drugs are safe for certain users, whether Pfizer failed to properly warn consumers of this risk, and whether doctors overprescribe statins after a serious cardiovascular event has occurred.
Other recent studies have linked Lipitor and other statins to an increased risk for developing cataracts, which is a vision disorder causing the lens of the eye to become cloudy. These side effects can have a huge negative impact on Lipitor users' quality of life.
Pradaxa is the brand name of a blood thinner, dabigatran, used to reduce the risk of stroke or blood clots. It is most frequently prescribed to people with irregular heartbeats, or atrial fibrillation - a condition that typically affects the elderly.
The safety of Pradaxa, however, is being questioned. The U.S. Food and Drug Administration (FDA) in 2011 received reports of 3,781 adverse side effects and 542 deaths. Some of those serious side effects include:
- Heart attack (myocardial infarction)
- Acute coronary syndrome (ACS)
- Stomach pain
- Gastrointestinal symptoms like dyspepsia
After receiving reports linking Pradaxa to bleeding, the FDA in December 2011 announced a safety review of Pradaxa. The agency wants to find out if bleeding events are more frequent with Pradaxa patients than expected. According to an Aug. 19, 2012, report in USA Today, Pradaxa's adverse reports and deaths were higher than all other monitored drugs in 2011. Millions of people take the drug twice a day, and sales are greater than $1 billion.
According to an Archives of Internal Medicine study in January 2012, researchers found a link between Pradaxa and slightly higher risk of heart attack or acute coronary syndrome when compared with similar medicines. Researchers compared the use of Pradaxa to other anticoagulants like warfarin, enoxaparin or a placebo and found the increased risk ranged from 27 to 33 percent in patients who used Pradaxa.
Reglan (metoclopramide) is a medication used to treat persistent heartburn and other conditions of the stomach or intestines. Some pregnant women have used Reglan to fight the symptoms of morning sickness or to stimulate lactation. However, Reglan use has been linked to a serious movement disorder called tardive dyskinesia, which leads to the following rarely reversible symptoms:
- Lip smacking
- Puckering and pursing of the lips
- Rapid eye movements or blinking
- Tongue protrusion
- Rapid movements of the fingers, arms, legs and trunk
Reglan also is linked to Neuroleptic Malignant Syndrome (NMS), a rare, but life-threatening disorder characterized by muscle rigidity.
The FDA has only approved Reglan for short-term use, up to 12 weeks. However, 30 percent of Reglan patients are given the drug for 12 months or longer. The risk of adverse side effects increases when the drug is used over a long period of time.
Risperdal, or its generic equivalent risperidone, is an antipsychotic used to treat disorders such as schizophrenia, bipolar disorder and certain behavioral disorders. The drug was originally approved in 1993 specifically to treat schizophrenia in adults. In 2006 and 2007, the FDA approved several additional uses for the medication, including treatment of several disorders in children.
Risperdal lawsuits tend to focus on inappropriate marketing conducted by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Specifically, lawsuits allege that the drug was marketed for use in children shortly after the medication was first approved in 1993, even though the FDA did not approve the drug for any use in children until 2006. Janssen Pharmaceuticals first sought approval to use the drug for pediatric patients in 1996, but the application was denied. At that time, the FDA noted suspicion that the drug was already being used "off-label" for pediatric patients.
Risperdal has been shown to over-stimulate the pituitary gland, which can cause a condition called gynecomastia, the development of breast tissue in males. Boys who develop gynecomastia can suffer significant emotional and mental trauma in addition to the physical changes. Risperdal is also associated with premature breast development in girls and other serious risks such as movement disorders, diabetes and heart disease.
The prescription drug Taxotere, or its generic equivalent docetaxel, is primarily prescribed to women undergoing treatment for breast cancer. It is a chemotherapy drug injected intravenously and used to prevent cancer cells from growing and dividing.
Unfortunately, Taxotere has been linked to permanent alopecia - that is, loss of hair. Taxotere's manufacturer was aware of this side effect as early as 2005, yet the prescription label was not updated until 2016. Moreover, an alternative drug, Taxol, offers similarly effective treatment without the side effect of permanent hair loss.
Because of the manufacturer's failure to warn patients of the side effects, thousands of women are now permanently bald. Had they been properly warned of the dangers of Taxotere, they could have used Taxol. While hair loss is commonly associated with cancer treatment, it is a very rare side effect of treatment for breast cancer. You need to contact us if you or a loved one suffered permanent hair loss during breast cancer treatment. Taxotere is likely to blame - and you may be entitled to compensation.
In early 2014, the U.S. Food and Drug Administration (FDA) issued a medical safety alert warning doctors of potentially harmful side effects and cardiovascular risks associated with testosterone therapy medication for men. The agency issued the statement after studies by the U.S. National Cancer Institute and University of California, Los Angeles, found an increased risk of heart attack, stroke, pulmonary embolism (PE), deep vein thrombosis (DVT) and other potentially fatal health complications.
- Men over age 65 face a two-fold risk of suffering heart attack within the first 90 days of undergoing testosterone therapy or taking testosterone medication, the UCLA study found.
- Men age 65 and younger with a history of heart disease could face a two- to three-fold risk of heart attack and other adverse cardiovascular reactions, according to UCLA researchers.
- Testosterone therapy patients face a nearly 30 percent increased risk of heart attack, stroke or death when compared to patients not on testosterone medication, according to a Journal of the American Medical Association study.
- Men with the following conditions who are using testosterone treatment: artery blockage, diabetes, high cholesterol, obesity, plaque buildup, a prior heart attack.
Testosterone treatment products come in the form of gels, creams, injections and pills and are marketed under the following brand names:
The pharmaceutical companies that manufacture and market testosterone treatment products stand to gain significant profits. Testosterone therapy is a billion-dollar industry that grew fivefold between 2000 and 2011. An estimated 5.3 million prescriptions for testosterone treatment were written in 2011 alone, thanks in part to aggressive marketing from pharmaceutical companies,
In their rush to make profits, these companies sometimes fail to adequately warn both medical professionals and consumers about potentially dangerous side effects. They might even withhold this important information from the public, leaving millions of men at risk.
You may be one of the millions of men who have used Viagra (sildenafil citrate) since it was approved by the Food and Drug Administration in March 1998. The blockbuster erectile dysfunction drug has been the target of many lawsuits over a variety of claims. Other drugs used to treat impotence, including Levitra (vardenafil) and Cialis (tadalafil), have also been linked to serious side effects including blurry vision and hearing problems. The vision problems are known scientifically as "non-arteritic anterior ischemic optic neuropathy (NAION)." The FDA in 2005 ordered Pfizer to include warnings on the label about vision loss.
More recently, some men who have used Viagra have needed treatment for melanoma (skin cancer). A 2014 study published in JAMA Internal Medicine reviewed data involving more than 25,000 men over a 10-year period. After learning that at least 142 men using Viagra were diagnosed with skin cancer, researchers concluded their use of the medication was "significantly" linked to an increased risk of cancer. In fact, the study found that men using Viagra face a skin cancer risk that is nearly double compared to men who do not take the drug.
Cialis and Levitra are similar to Viagra, but the two drugs were not included in the study because they were not approved by the FDA when the study began. However, these two drugs last longer in the body than Viagra does, which means they may pose an even greater cancer risk.
Xarelto is an anticoagulant (blood-thinner) prescribed to people who are at risk of deep vein thrombosis (DVT) and pulmonary embolism. The U.S. Food and Drug Administration approved the product in July 2011.
Developed jointly by Bayer AG and Johnson & Johnson's Janssen Pharmaceuticals, Xarelto has been marketed as a new oral blood thinner treatment alternative to warfarin (Coumadin). Research has found that bleeding events occur more commonly in Xarelto patients than patients on either warfarin or Pradaxa (another blood-thinner).
Internal bleeding can be a difficult medical condition to diagnose. These are some warning signs:
- Unusual bleeding in the gums or from the nose and unusually heavy menstrual bleeding
- Bleeding in the stools (bright red or black in color)
- Blood clots
- Vomiting blood
- Headaches or dizziness
- Pain, swelling or new drainage at wound sites
Alarmingly, no available antidote exists for people who suffer bleeding complications.
This controversial birth control device was designed to prevent women from getting pregnant by inserting a metal coil inside the fallopian tubes, leading to sterilization. Conceptus created this product, which was first sold in 2002. Bayer AG acquired the rights to Essure in 2013. For years, Essure has been the subject of numerous lawsuits and other legal action due to injuries caused by the device. Thousands of women have experienced serious medical problems due to using Essure, including:
- Internal bleeding
- Severe pain
- Tubal perforations
- Possible Essure-related deaths
Due to these risks, Essure will soon no longer be sold in the United States. However, women who previously used Essure may still be entitled to compensation. Our law firm can help.
Metal-on-metal hip implants are devices with ball and socket components made of metal. The two types of metal-on-metal hip implants are traditional total hip replacement systems and resurfacing hip systems. When the metal ball and cup components rub together as a patient walks or runs, the device may produce shards of metallic debris that destroys the tissue and bone. Soft tissue damage may result in pain, implant loosening, device failure and the need to have the device surgically removed and replaced with another hip implant.
Other side effects linked to defective metal-on-metal hip devices include bone loss and destruction of tissues like tendons, muscle, and ligaments around the hip joint.
In particular, the DePuy ASR hip replacement system did not go through a thorough pre-market approval process with the FDA, which resulted in an unusually high number of early failure rates often requiring additional surgery. As a result, the manufacturer issued a recall of two types of hip implants.
The two products recalled are the DePuy ASR Hip Resurfacing System (launched in 2003) and DePuy ASR XL Acetabular System (launched in 2004). According to DePuy, 1 in 8 patients who received either of the products needed to have a revision surgery, or a second surgery, within five years. About 93,000 people may be affected by the product recall.
Recently, a $2.5 billion settlement was announced. DePuy's parent company, Johnson & Johnson, agreed to the settlement to resolve thousands of lawsuits.
DePuy is not the only manufacturer to run into issues with defective hip replacements. Stryker Orthopaedics issued a voluntary recall on certain hip implant models in July 2012 after reports of complications causing tissue inflammation and infection and metal toxicity. According to the company's own statement, the Stryker Rejuvenate and ABG II hip stems contain metal components that may rub together and cause metal debris to become loose.
Stryker had sold about 20,000 of the devices in the United States prior to the recall, which means thousands were put at risk of suffering from metal ion poisoning, or metallosis, hip replacement failure and other devastating side effects.
Regardless of whether they are experiencing the adverse symptoms, all hip replacement patients who had surgery since 2003 should consult with their doctors about these hip recalls. The doctor may need to scan or X-ray the hip and conduct a blood test. If a serious problem is discovered, a second hip replacement surgery may be required.